Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-07-10 pm EDT			5-day change	1st Jan Change
790.65 ^USD	+0.47%		+1.46%	+2.42%

Jul. 10	Morgan Stanley Adjusts Price Target on Eli Lilly to $1,135 From $1,133, Maintains Overweight Rating	MT
Jul. 09	Sector Update: Health Care Stocks Higher Late Afternoon	MT

WeightWatchers to exit process to cut $1.15 billion debt next week

Published on 06/17/2025 at 16:14

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Eli Lilly and Company

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,135 From $1,133, Maintains Overweight Rating	Jul. 10	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Jul. 09	MT
Sector Update: Health Care	Jul. 09	MT
Öhman Health and New Technology Fund Rises 3.9% in June - Camurus Surges After Eli Lilly Partnership	Jul. 09	FW
Eli Lilly Seen Benefiting From Higher Zepbound Sales in Q2, BofA Says	Jul. 09	MT
Eli Lilly: new recommended dosage for Kisunla	Jul. 09	CF
Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease	Jul. 09	CI
Eli Lilly Gets FDA Approval for Updated Kisunla Dosing for Alzheimer's	Jul. 09	MT
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	Jul. 09	RE
Eli Lilly FDA approves updated label for Kisunla	Jul. 09	RE
US FDA approves gradual dosing for Lilly Alzheimer's drug	Jul. 09	RE
Trump says pharmaceutical tariffs could reach 200%	Jul. 08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
WeightWatchers names new medical chief, plans to offer menopause therapy and support	Jul. 08	RE
Sector Update: Tech	Jul. 07	MT
Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	Jul. 07	MT
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
How Novo Nordisk misread the US market for its weight loss sensation	Jul. 01	RE
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	Jul. 01	MT
China's Innogen expects to complete weight-loss drug trials next year	Jul. 01	RE
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	Jul. 01	MT
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low	Jun. 30	RE
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low	Jun. 30	RE
Eli Lilly Wins Indian Regulatory Nod for Mounjaro Rollout	Jun. 29	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

47,000

Sector

Pharmaceuticals

Calendar

Aug. 07 - Q2 2025 Earnings Release

More about the company